CN1662511B - 瑞波西汀的药物盐 - Google Patents
瑞波西汀的药物盐 Download PDFInfo
- Publication number
- CN1662511B CN1662511B CN038139839A CN03813983A CN1662511B CN 1662511 B CN1662511 B CN 1662511B CN 038139839 A CN038139839 A CN 038139839A CN 03813983 A CN03813983 A CN 03813983A CN 1662511 B CN1662511 B CN 1662511B
- Authority
- CN
- China
- Prior art keywords
- reboxetine
- obstacle
- salt
- disorder
- morpholine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Anesthesiology (AREA)
- Reproductive Health (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Child & Adolescent Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
角度(°2θ) | 相对强度 |
6.45 | 39.3 |
9.00 | 37.9 |
12.85 | 51.5 |
16.85 | 44.7 |
18.10 | 27.7 |
19.30 | 19.8 |
21.20 | 51.9 |
22.05 | 16.9 |
24.05 | 100.0 |
25.70 | 20.1 |
30.10 | 27.7 |
30.30 | 29.0 |
30.90 | 18.9 |
角度(°2θ) | 相对强度 |
6.40 | 28.9 |
角度(°2θ) | 相对强度 |
8.90 | 71.9 |
12.75 | 92.1 |
16.65 | 94.0 |
17.40 | 31.5 |
17.85 | 30.2 |
21.30 | 39.9 |
22.25 | 40.1 |
23.20 | 29.9 |
24.05 | 100 |
25.60 | 32.0 |
25.70 | 31.7 |
29.85 | 35.4 |
相对湿度(%) | 琥珀酸盐水吸附% | 富马酸盐水吸附% |
20 | 0.03 | 0.06 |
35 | 0.06 | 0.11 |
50 | 0.10 | 0.16 |
65 | 0.14 | 0.21 |
80 | 0.21 | 0.31 |
90 | 0.29 | 0.47 |
相对湿度(%) | 吸附循环水含量% | 解吸循环水含量% |
0 | 0.0 | 4.3 |
20 | 0.5 | 4.5 |
35 | 0.6 | 4.6 |
50 | 0.7 | 4.6 |
65 | 0.9 | 4.6 |
80 | 4.5 | 4.7 |
90 | 8.7 | 8.7 |
盐 | 琥珀酸盐 | 富马酸盐 | 甲磺酸盐 |
水分吸附效果→ | 取决于环境相对湿度的可逆水吸附。晶型不变化(图3) | 取决于环境相对湿度的可逆水吸附。晶型不变化(图3) | 因为水吸附的结晶不可逆变化。甚至当药物再暴露于低湿度时水的保留(图4) |
Claims (10)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02077366.9 | 2002-06-17 | ||
EP02077366 | 2002-06-17 | ||
PCT/EP2003/005261 WO2003106441A1 (en) | 2002-06-17 | 2003-06-04 | Pharmaceutical salts of reboxetine |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA200810093308XA Division CN101298440A (zh) | 2002-06-17 | 2003-06-04 | 瑞波西汀的药物盐 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1662511A CN1662511A (zh) | 2005-08-31 |
CN1662511B true CN1662511B (zh) | 2010-06-09 |
Family
ID=29724495
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN038139839A Expired - Fee Related CN1662511B (zh) | 2002-06-17 | 2003-06-04 | 瑞波西汀的药物盐 |
CNA200810093308XA Pending CN101298440A (zh) | 2002-06-17 | 2003-06-04 | 瑞波西汀的药物盐 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA200810093308XA Pending CN101298440A (zh) | 2002-06-17 | 2003-06-04 | 瑞波西汀的药物盐 |
Country Status (24)
Country | Link |
---|---|
US (2) | US20070010517A1 (zh) |
EP (1) | EP1515959B1 (zh) |
JP (1) | JP4563172B2 (zh) |
KR (1) | KR100779786B1 (zh) |
CN (2) | CN1662511B (zh) |
AR (1) | AR040222A1 (zh) |
AT (1) | ATE439354T1 (zh) |
AU (1) | AU2003227755B2 (zh) |
BR (1) | BR0311878A (zh) |
CA (1) | CA2489763C (zh) |
DE (1) | DE60328787D1 (zh) |
DK (1) | DK1515959T3 (zh) |
ES (1) | ES2328472T3 (zh) |
HK (1) | HK1077572A1 (zh) |
MX (1) | MXPA04011916A (zh) |
MY (1) | MY131231A (zh) |
NO (1) | NO329346B1 (zh) |
NZ (1) | NZ537023A (zh) |
PE (1) | PE20040565A1 (zh) |
PL (1) | PL375211A1 (zh) |
RU (1) | RU2286341C2 (zh) |
TW (1) | TWI267510B (zh) |
WO (1) | WO2003106441A1 (zh) |
ZA (1) | ZA200409624B (zh) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0319793D0 (en) | 2003-08-22 | 2003-09-24 | Lilly Co Eli | Pyridinylmorpholine derivatives |
WO2005082869A1 (en) * | 2004-02-20 | 2005-09-09 | Pharmacia & Upjohn Company Llc | Method for the preparation of aryl ethers |
US8580776B2 (en) * | 2007-07-10 | 2013-11-12 | The Board Of Trustees Of The University Of Illinois | Compositions and methods for treating neurodegenerating diseases |
US20100069389A1 (en) * | 2008-09-06 | 2010-03-18 | Bionevia Pharmaceuticals, Inc. | Novel forms of reboxetine |
US20190185438A1 (en) * | 2016-12-06 | 2019-06-20 | Tonix Pharmaceuticals Holding Corp. | Salts and polymorphs of esreboxetine |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2167407A (en) * | 1984-11-22 | 1986-05-29 | Erba Farmitalia | Enantiomers of phenoxy derivatives of benzyl morpholine and salts thereof |
US6028070A (en) * | 1997-09-23 | 2000-02-22 | Eli Lilly And Company | Treatment of oppositional defiant disorder |
US6046193A (en) * | 1997-09-23 | 2000-04-04 | Eli Lilly And Company | Treatment of attention-deficit/hyperactivity disorder |
US6391876B1 (en) * | 1998-04-13 | 2002-05-21 | Pharmacia And Upjohn Company | Reboxetine for treatment obsessive compulsive disorders and panic disorder |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA57107C2 (uk) * | 1997-09-23 | 2003-06-16 | Елі Ліллі Енд Компані | Спосіб лікування розладу поведінки |
SK286669B6 (sk) * | 1999-07-01 | 2009-03-05 | Pharmacia & Upjohn Company | Použitie opticky čistého (S,S)-reboxetínu alebo jeho farmaceuticky prijateľnej soli na výrobu lieku na liečenie alebo prevenciu periférnej neuropatie |
-
2003
- 2003-06-04 PL PL03375211A patent/PL375211A1/xx not_active Application Discontinuation
- 2003-06-04 CN CN038139839A patent/CN1662511B/zh not_active Expired - Fee Related
- 2003-06-04 AU AU2003227755A patent/AU2003227755B2/en not_active Ceased
- 2003-06-04 DE DE60328787T patent/DE60328787D1/de not_active Expired - Lifetime
- 2003-06-04 CA CA002489763A patent/CA2489763C/en not_active Expired - Fee Related
- 2003-06-04 RU RU2005100846/04A patent/RU2286341C2/ru not_active IP Right Cessation
- 2003-06-04 BR BR0311878-9A patent/BR0311878A/pt not_active IP Right Cessation
- 2003-06-04 AT AT03725195T patent/ATE439354T1/de not_active IP Right Cessation
- 2003-06-04 EP EP03725195A patent/EP1515959B1/en not_active Expired - Lifetime
- 2003-06-04 WO PCT/EP2003/005261 patent/WO2003106441A1/en active Application Filing
- 2003-06-04 DK DK03725195T patent/DK1515959T3/da active
- 2003-06-04 JP JP2004513273A patent/JP4563172B2/ja not_active Expired - Fee Related
- 2003-06-04 US US10/588,808 patent/US20070010517A1/en not_active Abandoned
- 2003-06-04 ES ES03725195T patent/ES2328472T3/es not_active Expired - Lifetime
- 2003-06-04 KR KR1020047020412A patent/KR100779786B1/ko not_active IP Right Cessation
- 2003-06-04 MX MXPA04011916A patent/MXPA04011916A/es active IP Right Grant
- 2003-06-04 CN CNA200810093308XA patent/CN101298440A/zh active Pending
- 2003-06-04 NZ NZ537023A patent/NZ537023A/en unknown
- 2003-06-11 MY MYPI20032183A patent/MY131231A/en unknown
- 2003-06-11 TW TW092115889A patent/TWI267510B/zh not_active IP Right Cessation
- 2003-06-13 AR ARP030102115A patent/AR040222A1/es unknown
- 2003-06-17 PE PE2003000594A patent/PE20040565A1/es not_active Application Discontinuation
-
2004
- 2004-11-29 ZA ZA200409624A patent/ZA200409624B/xx unknown
-
2005
- 2005-01-12 NO NO20050183A patent/NO329346B1/no not_active IP Right Cessation
- 2005-10-26 HK HK05109498.3A patent/HK1077572A1/xx not_active IP Right Cessation
-
2009
- 2009-05-21 US US12/469,780 patent/US20090291953A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2167407A (en) * | 1984-11-22 | 1986-05-29 | Erba Farmitalia | Enantiomers of phenoxy derivatives of benzyl morpholine and salts thereof |
US6028070A (en) * | 1997-09-23 | 2000-02-22 | Eli Lilly And Company | Treatment of oppositional defiant disorder |
US6046193A (en) * | 1997-09-23 | 2000-04-04 | Eli Lilly And Company | Treatment of attention-deficit/hyperactivity disorder |
US6391876B1 (en) * | 1998-04-13 | 2002-05-21 | Pharmacia And Upjohn Company | Reboxetine for treatment obsessive compulsive disorders and panic disorder |
Non-Patent Citations (6)
Title |
---|
Della Torre, A. |
Lazzari, E. |
Mazzini, G. |
Melloni, P. |
Melloni, P.;Della Torre, A.;Lazzari, E.;Mazzini, G.;Meroni,M..Configurational studies on2-[a-(2-ethoxyphenoxy)benzyl]morpholine FCE 20124.Tetrahedronvol.41 no.7.1985,41(7),1393-9. * |
Meroni,M..Configurational studies on2-[a-(2-ethoxyphenoxy)benzyl]morpholine FCE 20124.Tetrahedronvol.41 no.7.1985,41(7),1393-9. |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101379064B (zh) | 二氢蝶啶酮衍生物的三氢氯酸盐形式及其制备方法 | |
KR101627901B1 (ko) | 인지기능 장애의 치료를 위한, 세로토닌 재흡수, 5-ht3 및 5-ht1a 활성이 조합된 화합물로서의 1-[2-(2,4-디메틸페닐술파닐)-페닐]피페라진 | |
KR101536023B1 (ko) | 조합된 sert, 5-ht3 및 5-ht1a 활성을 가진 화합물의 치료 용도 | |
KR101459168B1 (ko) | 수면 및 인지 관련 우울증에서의 통증 또는 잔여 증상의 치료를 위한, 세로토닌 재흡수, 5-ht3 및 5-ht1a 활성을 갖는 화합물인 1-[2-(2,4-디메틸페닐술파닐)페닐]피페라진 | |
CN1662511B (zh) | 瑞波西汀的药物盐 | |
JP3554338B2 (ja) | 新規な塩 | |
EP1451166B1 (en) | Citric acid salt of a therapeutic compound and pharmaceutical compositions thereof | |
CN102770416B (zh) | 美他沙酮共晶体 | |
CN1172920C (zh) | 制备2-(4-烷基-1-哌嗪基)-苯甲醛和-亚苄基化合物的方法 | |
WO2024145663A2 (en) | Salt forms of r-mdma and methods using the same | |
MX2011002728A (es) | Nueva sal de derivado de morfolina. | |
JP2016503033A (ja) | 多形体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1077572 Country of ref document: HK |
|
ASS | Succession or assignment of patent right |
Owner name: ITALY PFIZER INC. Free format text: FORMER OWNER: PHARMACIA ITALIAN CO., LTD. Effective date: 20080523 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20080523 Address after: Italy Latina Applicant after: Pharmacia Italia SPA Address before: Milan Italy Applicant before: Pharmacia Italia SPA |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1077572 Country of ref document: HK |
|
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20100609 Termination date: 20110604 |